Results 231 to 240 of about 214,894 (274)

Exploring GABA - A Receptor Subunit Mutations and Their Role in Epilepsy Pathophysiology.

J Pharm Bioallied Sci
Chelvakumar EG, Anand CD, Ramachandran K.   +2 more
europepmc   +1 more source

Small-Molecule Ligands of Rhodopsin and Their Therapeutic Potential in Retina Degeneration. [PDF]

Int J Mol Sci
Pashandi Z, Jastrzebska B.
europepmc   +1 more source

Formation of Condition‐Dependent Alpha‐Synuclein Fibril Strain in Artificial Cerebrospinal Fluid

Advanced Science, EarlyView.
α‐synuclein aggregation in artificial cerebrospinal fluid (aCSF) leads to a distinct conformation with an electron density pocket motif found in aggregates from PD and MSA patients. Such fibrils has low stability outside the reaction conditions, hinting about the influence of cerebrospinal fluid components not only on the formation, but also on the ...
Rūta Sniečkutė, Darius Šulskis, Arūnė Jocytė, Urtė Venclovaitė, Rimgailė Tamulytė, Mantas Žiaunys, Vytautas Smirnovas, Andrius Sakalauskas   +7 more
wiley   +1 more source

Agonist efficacy at the β₂AR is driven by agonist-induced differences in receptor affinity for the G_sprotein, not ligand binding kinetics [PDF]

Clare R. Harwood, David A. Sykes, Theo Redfern-Nichols, Graham Ladds, Stephen J. Briddon, Dmitry B. Veprintsev   +5 more
openalex   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, EarlyView.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics. [PDF]

Proc Natl Acad Sci U S A
Teplensky MH, Bourgeois JN, Kudruk S, Hurst Petrosko S, Mirkin CA.   +4 more
europepmc   +1 more source

Onion‐Mitochondria Inhibit Lipopolysaccharide‐Induced Acute Lung Injury by Shaping Lung Macrophage Mitochondrial Function

Advanced Science, EarlyView.
Proposed model of orally administered onion mitochondria (O‐Mit) uptake by lung macrophages and fuse with macrophage mitochondria (M‐Mit). This fusion reprograms the metabolism of dysfunctional M‐Mit in lipopolysaccharide‐induced murine acute lung injury by modulating dynamin‐related protein 1 (DRP1) phosphorylation and cardiolipin peroxidation ...
Qingbo Xu, Yun Teng, Yinan Huang, Jingyao Mu, Lucy Teng, Hongjia Qian, Qiming Huang, Minmin Liu, Yi Zou, Lifeng Zhang, Michael L Merchant, Xiang Zhang, Jun Yan, Huang‐Ge Zhang   +13 more
wiley   +1 more source

Beyond the 1:1 Ligand–Protein Paradigm: An In Silico Assay for Competitive Ligand Binding

Cardenas VB, Raniolo S, Conflitti P, Limongelli V.   +3 more
europepmc   +1 more source

Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells. [PDF]

Biomolecules
Li Z, Schneikert J, Bal G, Zuberbier T, Babina M.   +4 more
europepmc   +1 more source

Tumor‐Informed ctDNA in Guiding First‐Line Immunochemotherapy in Advanced Non‐Small Cell Lung Cancers

Advanced Science, EarlyView.
Tumor‐informed circulating tumor DNA (ctDNA) analysis identifies patients with advanced non‐small cell lung cancer (NSCLC) who benefit from first‐line immunotherapy plus chemotherapy. Longitudinal ctDNA monitoring further reflects therapeutic response and predicts prognosis beyond imaging.
Kailun Fei, Jie Zhao, Jiachen Xu, Jianchun Duan, Chengcheng Li, Wenchuan Xie, Jia Zhong, Guoqiang Wang, Yu Xu, Boyang Sun, Rui Wan, Hua Bai, Qinxiang Guo, Wei Guo, Shangli Cai, Zhijie Wang, Jie Wang   +16 more
wiley   +1 more source